Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Cancer biology & therapy - 2 Sept 2017

Lev Avital, Deihimi Safoora, Shagisultanova Elena, Xiu Joanne, Lulla Amriti R, Dicker David T, El-Deiry Wafik S

Abstract excerpt

Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the United States. We analyzed 26 MSI-High and 558 non-MSI-High CRC tumors. BRCA2 mutations were highly enriched (50%) in MSI-High CRC. Immunohistochemistry showed that BRCA2-mutated MSI-High CRC had high c-MET (64%) expression compared with BRCA-WT (17%). We hypothesized a mechanistic link between BRCA2-deficiency and c-MET overexpression and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Mitomycin

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28886275
DOI: 10.1080/15384047.2017.1364323
PMCID: PMC5663405

Genes

BRCA2
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.PMID 28886275Read ↗

Update on Emerging Therapies for Advanced Colorectal Cancer.Semantic proximity Read ↗

Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study.Semantic proximity Read ↗

Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studySemantic proximity Read ↗

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.Semantic proximity Read ↗

Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal CancersSemantic proximity Read ↗

B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.Semantic proximity Read ↗

Majority of B2M -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-HighSemantic proximity Read ↗

Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity Read ↗

The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Implications of mismatch repair-deficient status on management of early stage colorectal cancer.Semantic proximity Read ↗

Targeted Therapy for Colorectal Cancer.Semantic proximity Read ↗

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.